Claims Court Role In Pipeline Patents Urged; Amgen Wants Bolar Limited
Executive Summary
Patent restoration requests for drugs in the pipeline at the time of enactment of the Waxman/Hatch Act could be referred to the Federal Court of Claims for resolution, U.S. Federal Court of Appeals Judge Randall Rader suggested June 10 at a panel sponsored by the International Intellectual Property and Congressional Economic Leadership Institutes.
You may also be interested in...
PTO Not Qualified To Judge FDA Review of "Pipeline" Products - Barr
Proposed legislation to reform the drug patent term restoration process could undercut FDA's "scientific judgements" by transferring undue authority to the Patent and Trademark Office, Sen. Leahy (D-Vt.) said during the Senate Judiciary committee's Aug. 4 hearing, "Pipeline Drugs: Proposed Remedies for Relief in S 1172."
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011